E Fund Management Co. Ltd. Grows Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

E Fund Management Co. Ltd. grew its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 152.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 10,479 shares of the company’s stock after purchasing an additional 6,335 shares during the period. E Fund Management Co. Ltd.’s holdings in Vaxcyte were worth $858,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. CIBC Asset Management Inc raised its holdings in Vaxcyte by 3.6% in the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock worth $358,000 after acquiring an additional 110 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after acquiring an additional 260 shares during the last quarter. Amalgamated Bank raised its holdings in Vaxcyte by 8.6% in the 3rd quarter. Amalgamated Bank now owns 4,081 shares of the company’s stock worth $466,000 after acquiring an additional 322 shares during the last quarter. KBC Group NV raised its holdings in Vaxcyte by 13.6% in the 3rd quarter. KBC Group NV now owns 2,683 shares of the company’s stock worth $307,000 after acquiring an additional 322 shares during the last quarter. Finally, Whipplewood Advisors LLC purchased a new position in Vaxcyte in the 4th quarter worth approximately $28,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective for the company. Guggenheim reaffirmed a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $147.50.

Insider Buying and Selling

In related news, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares of the company’s stock, valued at approximately $11,351,794.37. This represents a 4.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $92.25, for a total transaction of $218,263.50. Following the completion of the transaction, the chief executive officer now directly owns 136,215 shares of the company’s stock, valued at $12,565,833.75. This represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,616 shares of company stock valued at $4,768,521. Company insiders own 3.10% of the company’s stock.

Vaxcyte Price Performance

Shares of PCVX stock opened at $71.18 on Friday. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06. The firm has a fifty day moving average price of $83.33 and a 200-day moving average price of $94.51. The company has a market cap of $9.17 billion, a price-to-earnings ratio of -15.47 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. Equities research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.